NEWS DETAIL

In the SERENA-6 trial, carmestrant combination therapy delayed the time to first disease progression by 55% and the time to second disease progression by 37% in patients with advanced HR-positive breast cancer with ESR1 tumor mutations.

June 2, 2026 – Further positive results from the Phase III SERENA-6 trial showed that AstraZeneca's carmestrant in combination with cyclin-dependent kinase (CDK) 4/6 inhibitors – p…

Medical Information June 30, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Products Mentioned in This Article

These products were automatically matched from the article title, summary, and full content.

Frequently Asked Questions

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Pabocicni – Palbociclib – Buy online.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.